SAI PARENTERALS LIMITED SAIPARENT NSEPHARMA

Healthcare · Drug Manufacturers - General · India

https://www.saiparenterals.com

Sai Parenteral's Limited, a pharmaceutical formulations company, engages in the branded generic formulations and contract development and manufacturing businesses in India and internationally. Its portfolio includes formulation products across various therapeutic areas, such as cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements, analgesics, and dermatology in various dosage forms, including injectables, tablets, capsules, liquid orals, and ointments. The company was founded in 1988 and is based in Hyderabad, India.

Market & Price

Market Cap

₹2,146.67 Cr

Current Price

₹485.90

High / Low (52W)

₹509.90 / ₹405.70

Beta

Valuation

Stock P/E

109.93

Industry PE

37.60

Forward P/E

PEG Ratio

Book Value

₹56.16

Price to Book

8.65

P/S

5.63

EV/EBITDA

43.19

Dividend Yield

Profitability & Returns

ROCE

17.92%

ROE

4.83%

ROA

1.61%

Profit Margin

3.74%

Op Margin

2.68%

EPS (Latest Qtr)

₹-

EPS (TTM)

₹4.42

Balance Sheet & Liquidity

Debt/Equity

0.49

Quick Ratio

1.04

Current Ratio

1.44

Debt

₹242.91 Cr

Total Assets

₹723.58 Cr

Current Assets

₹384.54 Cr

Working Capital

₹-91.46 Cr

Ownership

Promoter Holding

70.68%

Chg in Prom Hold

FII / Inst Holding

8.43%

Chg in FII Hold

Financial Snapshot

Enterprise Value

₹1,671.39 Cr

Total Revenue (TTM)

₹381.00 Cr

EBITDA

₹38.70 Cr

Free Cash Flow

₹-218.66 Cr

Operating Cash Flow

₹93.05 Cr

Shares Outstanding

₹4.42 Cr

Gross Margin

36.42%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

126.13%

Profit 5Y

111.79%

Revenue (YoY)

Earnings (YoY)

PROS

Compounding revenue at 126.1% over 5 years.
Profit CAGR of 111.8% over 5 years.

CONS

Trading at a high P/E of 109.9.

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	SAIPARENT SAI PARENTERALS LIMITED NSEPHARMA	485.90	109.93	₹2,146.67 Cr	-	17.92%	4.83%	126.13%	111.79%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2023	Mar 2024	Mar 2025
Revenue	96.80 Cr	153.76 Cr	494.96 Cr
Cost of Revenue	57.95 Cr	94.97 Cr	270.27 Cr
Gross Profit	38.84 Cr	58.80 Cr	224.69 Cr
Operating Expenses	22.13 Cr	33.05 Cr	193.08 Cr
Operating Income	16.72 Cr	25.75 Cr	31.61 Cr
EBITDA	18.77 Cr	33.10 Cr	54.35 Cr
Interest Expense	5.72 Cr	11.12 Cr	16.52 Cr
Pretax Income	7.25 Cr	12.55 Cr	27.85 Cr
Tax Provision	2.88 Cr	4.14 Cr	8.22 Cr
Net Income	4.38 Cr	8.41 Cr	19.63 Cr
Diluted EPS	0.99	1.90	4.44

Compounded Sales Growth

5 Years:	126.13%
1 Year:	-

Compounded Profit Growth

5 Years:	111.79%
1 Year:	-

Stock Price Performance

1 Year:	+19.77%
6 Months:	-
3 Months:	-
1 Month:	+0.69%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2023	Mar 2024	Mar 2025
Total Assets	133.96 Cr	268.10 Cr	723.58 Cr
Current Assets	81.94 Cr	187.35 Cr	384.54 Cr
Cash & Equivalents	17.30 L	4.38 Cr	8.15 Cr
Inventory	13.19 Cr	37.21 Cr	151.33 Cr
Receivables	61.21 Cr	127.06 Cr	196.52 Cr
Total Liabilities	102.48 Cr	191.70 Cr	599.97 Cr
Current Liabilities	76.63 Cr	152.76 Cr	476.00 Cr
Long Term Debt	25.64 Cr	38.70 Cr	123.46 Cr
Total Debt	68.55 Cr	118.78 Cr	203.66 Cr
Total Equity	31.48 Cr	74.55 Cr	111.49 Cr
Shares Outstanding	4.42 Cr	4.42 Cr	4.42 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2023	Mar 2024	Mar 2025
Operating Cash Flow	-12.80 Cr	-29.76 Cr	33.15 Cr
Investing Cash Flow	-19.03 Cr	-46.32 Cr	43.50 L
Financing Cash Flow	23.98 Cr	78.57 Cr	-35.88 Cr
Capital Expenditure	-17.34 Cr	-44.10 Cr	-50.00 L
Free Cash Flow	-30.14 Cr	-73.86 Cr	32.65 Cr
Net Change in Cash	-7.85 Cr	2.48 Cr	-2.30 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2023	Mar 2024	Mar 2025
Gross Margin %	40.1%	38.2%	45.4%
Operating Margin %	17.3%	16.7%	6.4%
Net Margin %	4.5%	5.5%	4.0%
ROE %	13.9%	11.3%	17.6%
ROCE %	29.2%	22.3%	12.8%

Shareholding Pattern

Insiders

70.68%

Institutions

8.43%

Public Float

28.75%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SAIPARENT

No recent headlines available.

SAIPARENT · Healthcare